Mostrando 4 resultados de: 4
Filtros aplicados
Origen
scopus(4)
Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusAlpha-secretase ADAM10 regulation: Insights into Alzheimer’s disease treatment
ReviewAbstract: ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secretPalabras claves:ADAM10, Alzheimer’s disease, regulation, TreatmentAutores:Antoni Camins, Cominetti M.R., Manzine P.R., Peron R., Vatanabe I.P.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus